e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Asthma: risk factors and effect of anti-IgE
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Assesment of long-term omalizumab treatment in severe allergic asthma
E.S. Özgür, C. Özge, A. Ilvan, S. Atis Nayci (Mersin, Turkey)
Source:
Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Session:
Asthma: risk factors and effect of anti-IgE
Session type:
Poster Discussion
Number:
225
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E.S. Özgür, C. Özge, A. Ilvan, S. Atis Nayci (Mersin, Turkey). Assesment of long-term omalizumab treatment in severe allergic asthma. Eur Respir J 2012; 40: Suppl. 56, 225
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Pavic Michelle - 02.09.2012 11:54
Hi, I have found the data from your poster quite interesting and was wondering if you could email me a copy at: michelle.pavic@novartis.com, Thanks.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015
The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta
Source: International Congress 2016 – Asthma management
Year: 2016
Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019
Safety of omalizumab therapy in children with allergic asthma
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Treatment and outcomes in patients with asthma and allergic rhinitis
Source: Eur Respir J 2005; 26: Suppl. 49, 576s
Year: 2005
Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Improved symptom relief with omalizumab in the treatment of allergic rhinitis
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
Inflammatory biomarkers in the evaluation of two-year outcomes of omalizumab treatment in severe allergic asthma.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Effectiveness of omalizumab in improving quality of life in patients with ‘steroid-resistant‘ asthma and severe allergic rhinitis
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 663s
Year: 2006
Omalizumab, a novel therapy for severe allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001
Immunotherapy in severe asthma
Source: ERS webinar 2021: Immunotherapy in severe asthma
Year: 2021
Omalizumab in children with severe persistent allergic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
The efficacy of omalizumab in severe in asthma after treatment withdrawal
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept